Abstract

Through the continuation CCOP grant, Hematology-Oncology Associates of Central New York (HOACNY) can continue active participation in ongoing clinical cancer research and community based cancer control programs. HOACNY can continue to provide expertise in cancer prevention, cancer control, diagnosis, and treatment (curative, palliative, supportive) for the greater central New York area. This includes educating the health care consumers and providers in this area forming our referral base. Through HOACNY's affiliation with State University of New York Health Science Center and CALGB, which serves as our major research base, we are able to provide both cancer control protocols and state-of-the-art clinical trials to the surrounding population. The resources of the entire medical community will be employed toward this end. In addition to our major affiliation with CALGB, HOACNY will also utilize cancer control protocols as well as clinical cancer trials with NSABP and the Fox Chase Cancer Center so as to further achieve the above goals as they relate to the central New York area.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045389-07
Application #
3558577
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1987-07-21
Project End
1994-05-31
Budget Start
1993-06-08
Budget End
1994-05-31
Support Year
7
Fiscal Year
1993
Total Cost
Indirect Cost

  Institution

Name
Hematology-Oncology Associates/Ctl NY
Department
Type
DUNS #
City
East Syracuse
State
NY
Country
United States
Zip Code
13057

  Publications

Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20

Showing the most recent 10 out of 66 publications